New hope for kids with rare Muscle-Weakening disease
NCT ID NCT05644561
First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests a drug called ravulizumab in children aged 6 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug works in the body and if it helps control symptoms. Twelve participants will receive the drug through an IV and be monitored for about 18 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90078, United States
-
Research Site
Boston, Massachusetts, 02115, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Milan, 20133, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Torino, 10126, Italy
-
Research Site
Itabashi-ku, 173-0003, Japan
-
Research Site
Belgrade, 11000, Serbia
-
Research Site
Belgrade, 11070, Serbia
-
Research Site
Bern, 3010, Switzerland
Conditions
Explore the condition pages connected to this study.